ClinicalTrials.gg
TerminatedNCT04487405OVAnexUpdated Dec 26, 2023

A Multivariate Index Assay for Ovarian Cancer Risk Assessment in Women With Adnexal Mass and High-Risk Germline Variants

An observational study in Adnexal Mass, sponsored by Aspira Women's Health. Terminated at 9 sites in United States. Open to female participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-12-26.

Sponsored by Aspira Women's Health · Observational

How we know

Why this study was terminated
cohort C looked at feasibility of genetics \& protein to evaluate risk with a family hx of cancer or associated variant. Since few patients show these factors, this approach would not yield sufficient information to make inferences

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-control
Time perspective
Prospective
Enrollment
721
Ages
18 Years and older
Sex
Female
01

Study summary

The objective of this project is to validate the sensitivity, specificity, positive predictive value and negative predictive values of the AMRA blood test for assessing risk of cancer in women at high risk for ovarian cancer, due to the presence of a symptomatic adnexal mass.

02

Conditions studied

  • Adnexal Mass
03

In context

Lead sponsor

Aspira Women's Health is the lead sponsor of 3 studies on the registry; 1 is open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
Female
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Adult women with an ovarian adnexal mass, or in follow up due to the presence of BRCA1/2 and other germline DNA variants.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Female patient, 18 years of age or older diagnosed with an ovarian adnexal mass, or in follow-up due to the presence of BRCA1/2 and other germline DNA variants.
  • Patient reviewed, understood, and provided the PI with written to allow blood specimen to be used for research and release of medical information.

Exclusion criteria

Exclusion Criteria:

  • Patient is less than 18 years of age
  • Patient is not being treated in the U.S.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Case-control
Time perspective
Prospective
Enrollment
721 participants (actual)
Patient registry
No
Biospecimen retention
Samples without dna

Groups and cohorts

  • Group A

    Symptomatic with adnexal mass

    Device: OVAnex

  • Group B

    Asymptomatic with adnexal mass

    Device: OVAnex

  • Group C

    Women with a predisposition in developing ovarian cancer due to a positive, pathogenic variant

    Device: OVAnex

Interventions

  • DeviceOVAnex

    OVAnex is a multivarite index assay assessing ovarian cancer risk

06

What researchers measure

Primary outcomes

  1. OVAnex

    OVAnex is a multivariate index assay assessing ovarian cancer risk. The Ovanex MIA uses seven biomarkers with a stepwise algorithm to generate a risk score which ranges from 0 to 20.

    Time frame: 12 months

07

Study locations

9 sites
  • Women's Health Arizona
    Chandler, Arizona 85224, United States
  • Altus Research
    Lake Worth, Florida 33461, United States
  • MidTown OBGYN
    Columbus, Georgia 31901, United States
  • Premier OBGYN of Minnesota
    Eden Prairie, Minnesota 55344, United States
  • Square Care Health
    New Hyde Park, New York 11040, United States
  • Northwell Health
    New Hyde Park, New York 11042, United States
  • Seven Hills Clinical Research Group
    Cincinnati, Ohio 45211, United States
  • May Grant OB/GYN
    Lancaster, Pennsylvania 17601, United States
  • Hill Country OBGYN Associates
    Austin, Texas 78748, United States
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jun 2020 to primary completion in Dec 2023, 41 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2020
First posted
Jul 27, 2020
StartActual
Jun 25, 2020
Primary completionActual
Dec 15, 2023
CompletionActual
Dec 15, 2023
Last update
Dec 26, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 26, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04487405
Lead sponsor
Aspira Women's Health
Responsible party
Sponsor
First posted
Jul 27, 2020
Start date
Jun 25, 2020
Primary completion
Dec 15, 2023
Completion
Dec 15, 2023
Last update
Dec 26, 2023

Study contacts

Todd Pappas, PhD
principal investigator · Aspira Women's Health

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Dec 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion